文献速递消化、代谢与肾脏急症

小乳头括约肌切开术治疗胰腺分裂症相关特发性急性胰腺炎:一项随机临床试验

Minor Papillotomy for Treatment of Idiopathic Acute Pancreatitis With Pancreas Divisum: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在不明原因急性复发性胰腺炎合并胰腺分裂症的成人中,ERCP小乳头括约肌切开术未降低急性胰腺炎再发风险(调整HR 0.83,95%CI 0.49-1.41)。

这项多中心、假手术对照、双盲随机临床试验纳入148例有2次及以上急性胰腺炎发作且合并胰腺分裂症的成人,1:1随机接受ERCP小乳头括约肌切开术或假ERCP,中位随访34个月。主要终点随机化30天后急性胰腺炎发生:切开组34.7% vs 假手术组43.8%(调整HR 0.83,95%CI 0.49-1.41),未达统计学显著。慢性钙化性胰腺炎、糖尿病、外源性胰腺功能不全的发生率两组无差异。结论认为ERCP小乳头括约肌切开术不能降低急性胰腺炎再发或相关后遗症风险。

要点

  • 在不明原因急性复发性胰腺炎合并胰腺分裂症成人中,ERCP小乳头括约肌切开术未显著降低随机化30天后急性胰腺炎发生风险(34.7% vs 43.8%,调整HR 0.83,95%CI 0.49-1.41)。
  • 两组急性复发性胰腺炎发作频率的发病率比分别为切开组0.25(95%CI 0.18-0.34)与假手术组0.30(95%CI 0.23-0.41)。
  • 慢性钙化性胰腺炎(4.0% vs 2.7%,RD 0.01,95%CI -0.05至0.07)、糖尿病(15.8% vs 12.8%,RD 0.03,95%CI -0.13至0.19)、外源性胰腺功能不全(7.7% vs 17.2%,RD -0.10,95%CI -0.27至0.08)两组无差异。
  • 随机化30天内急性胰腺炎不良事件在切开组更常见(14.7% vs 8.2%,RD 0.06,95%CI -0.04至0.17)。

适用人群与场景

  • 成人(平均年龄54岁,标准差19.5岁;68.2%女性)有2次及以上急性胰腺炎发作且合并胰腺分裂症,病因不明。
  • 排除有其他急性胰腺炎病因或合并慢性钙化性胰腺炎的成人。
  • 研究在美国和加拿大21个转诊中心开展,非急诊或ICU场景。

研究设计与关键结果

  • 多中心、假手术对照、双盲随机临床试验,2018年9月1日至2024年8月30日在美国和加拿大21个转诊中心开展,纳入148例成人,1:1随机接受ERCP小乳头括约肌切开术或假ERCP,中位随访34个月(IQR 21.7-45.7个月)。
  • 主要终点随机化30天后急性胰腺炎发生:切开组26/75(34.7%)vs 假手术组32/73(43.8%),调整HR 0.83(95%CI 0.49-1.41)。
  • 急性复发性胰腺炎发作频率的发病率比:切开组0.25(95%CI 0.18-0.34)vs 假手术组0.30(95%CI 0.23-0.41)。
  • 慢性钙化性胰腺炎发生率切开组4.0% vs 假手术组2.7%,RD 0.01(95%CI -0.05至0.07);糖尿病15.8% vs 12.8%,RD 0.03(95%CI -0.13至0.19);外源性胰腺功能不全7.7% vs 17.2%,RD -0.10(95%CI -0.27至0.08),均无组间差异。
  • 随机化30天内急性胰腺炎不良事件:切开组14.7% vs 假手术组8.2%,RD 0.06(95%CI -0.04至0.17)。

证据类型、等级与局限

  • 证据类型:多中心、假手术对照、双盲随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在不明原因急性复发性胰腺炎合并胰腺分裂症患者中,ERCP小乳头括约肌切开术不降低另一次急性胰腺炎发作或相关后遗症的风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Pancreas divisum is implicated as an obstructive cause for acute pancreatitis. Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes. Even though this endoscopic procedure is widely used in practice, clinical trials are lacking.

OBJECTIVE: To determine whether ERCP with minor papillotomy reduces the risk of acute pancreatitis among adults with unexplained acute recurrent pancreatitis and pancreas divisum.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, sham-controlled, double-blind randomized clinical trial enrolled adults with 2 or more episodes of acute pancreatitis and pancreas divisum. Adults with other etiologies for acute pancreatitis or concomitant chronic calcific pancreatitis were excluded. The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada. Last follow-up occurred on February 15, 2025.

INTERVENTION: Participants were randomized in a 1:1 ratio to ERCP with minor papillotomy or sham ERCP.

MAIN OUTCOMES AND MEASURES: The primary outcome was development of acute pancreatitis more than 30 days after randomization as a time-to-event outcome. The secondary outcomes included acute pancreatitis episode frequency and development of chronic calcific pancreatitis, diabetes, and exocrine pancreatic dysfunction.

RESULTS: A total of 148 participants were randomized (mean age, 54 [SD, 19.5] years; 68.2% female; 95.3% non-Hispanic or Latino and 87.2% White; mean lifetime acute pancreatitis episodes, 3 [SD, 2]; mean duct diameter, 2.2 [SD, 1.3] mm) and followed up for a median of 34 months (IQR, 21.7-45.7 months). Of the 75 participants in the ERCP with minor papillotomy group, 26 (34.7%) developed acute pancreatitis compared with 32 of 73 participants (43.8%) in the sham ERCP group (adjusted hazard ratio, 0.83 [95% CI, 0.49 to 1.41]). The incidence rate ratio for acute recurrent pancreatitis episode frequency was 0.25 (95% CI, 0.18 to 0.34) in the ERCP with minor papillotomy group vs 0.30 (95% CI, 0.23 to 0.41) in the sham ERCP group. There were no between-group differences in frequency and incidence of chronic calcific pancreatitis (4.0% in the ERCP with minor papillotomy group vs 2.7% in the sham ERCP group; risk difference [RD], 0.01 [95% CI, -0.05 to 0.07]), diabetes (15.8% vs 12.8%, respectively; RD, 0.03 [95% CI, -0.13 to 0.19]), and exocrine pancreatic dysfunction (7.7% vs 17.2%; RD, -0.10 [95% CI, -0.27 to 0.08]). The adverse event of acute pancreatitis within 30 days of randomization occurred more frequently in the ERCP with minor papillotomy group (14.7%) vs the sham ERCP group (8.2%) (RD, 0.06 [95% CI, -0.04 to 0.17]).

CONCLUSIONS AND RELEVANCE: Among patients with unexplained acute recurrent pancreatitis and pancreas divisum, ERCP with minor papillotomy does not reduce the risk of another episode of acute pancreatitis or related sequelae.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03609944.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Coté GA, Durkalski-Mauldin V, Fogel EL, et al. Minor Papillotomy for Treatment of Idiopathic Acute Pancreatitis With Pancreas Divisum: A Randomized Clinical Trial. JAMA. 2026. PMID: 41533371. doi:10.1001/jama.2025.23988

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。